Beam Therapeutics Inc. (BEAM) SEC Filings & Earnings Calls

Clinical trial failure risk

“We are a clinical-stage company, and our programs are at a preclinical or clinical stage of development.” · word for word

Capital requirement risk

“We will need to raise additional capital to support our continuing operations and pursue our growth strategy.” · word for word

Regulatory approval risk

“We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from the sale of our product candidates in the near future.” · word for word

Clinical and regulatory risk: pipeline programs may fail or be delayed; BLA submission for risto-cel is a key catalyst.

“Beam expects to report updated data for the BEACON trial by year-end 2026 and submit a biologics license application (BLA) for risto-cel as early as year-end 2026.” · word for word

Cash burn: net loss of $122.7M per quarter; runway into mid-2029 depends on successful execution and potential additional financing.

“Net loss was $122.7 million... Cash runway expected to support operating plans into mid-2029.”

Clinical trial failure risk

“We are a clinical-stage company, and our programs are at a preclinical or clinical stage of development.” · word for word

Capital requirement risk

“We will need to raise additional capital to support our continuing operations and pursue our growth strategy.” · word for word

Regulatory approval risk

“We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from the sale of our product candidates in the near future.” · word for word

Clinical trial risk: BEAM-302 and risto-cel still in development; regulatory approval uncertain.

“BEAM-302 pivotal cohort not yet initiated; risto-cel BLA submission as early as year-end 2026.”

Cash burn: Net loss and increasing R&D/G&A expenses may pressure runway if timelines slip.

“Net loss $94.3M; R&D up 5.8%; G&A up 23.3% YoY.”

Clinical development risk for BEAM-304 and other pipeline programs.

“Preclinical data with both base editors demonstrate that BEAM-304 normalized plasma Phe levels in mouse models at clinically relevant doses.” · word for word

Regulatory approval risk for risto-cel BLA submission.

“U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026.” · word for word

No product revenue; reliance on collaboration revenue and financing

“Since our inception in January 2017, we have not generated any revenue from product sales, have generated only limited revenue from our license and collaboration agreements, and have incurred significant operating losses and negative cash flows from our operations.” · word for word

Significant operating cash burn

“Net cash used in operating activities for the year ended December 31, 2025 was $345.1 million” · word for word

R&D expense growth pressure

“Research and development expenses are expected to continue to increase as we advance clinical trials for risto-cel, BEAM-302, and BEAM-304” · word for word

Success payment obligations to Harvard and Broad

“We may owe Harvard and Broad Institute success payments of up to an additional $90.0 million each, which is payable at our election in cash or shares of our common stock.” · word for word

Milestone payment obligations from acquisition

“In addition, we may owe up to an additional $89.0 million in development, clinical and commercial milestones to former stockholders of an early-stage life sciences company acquired during the year ended December 31, 2025.” · word for word

Dependence on third-party patent licenses; standby agreement mitigates but does not eliminate risk.

“To ensure the Company has a continued license to the Patents in the event of a termination of the Kobe-Bio Palette License.” · word for word

Pre-revenue; depends on clinical and regulatory success.

“No approved products; all programs in clinical development.”

Manufacturing and regulatory risks for gene therapy products.

“CDRP program acceptance indicates CMC challenges.”

Clinical trial failure risk remains high for all pipeline programs; no approved products yet.

“All programs are in Phase 1/2; no revenue from product sales.”

Orbital acquisition proceeds uncertain; subject to closing conditions and adjustments.

“The Orbital acquisition is subject to the satisfaction of closing conditions, and the sale price is subject to certain financial adjustments and holdbacks.” · word for word

No product revenue and significant operating losses

“To date, we have not generated any revenue from product sales and do not expect to generate revenue from the sale of products for the foreseeable future.” · word for word

Dependence on additional capital

“Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing arrangements.” · word for word

Clinical trial and regulatory risk

“The development process and related regulatory processes are complex and uncertain, may be lengthy and expensive, and require, among other things, an indication that our products and product candidates are safe and effective.”